Hormone Refractory Prostate Cancer Terminated Phase 3 Trials for Docetaxel (DB01248)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone-Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

DBCOND0030609 (Hormone Refractory Prostate Cancer)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01083615A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Treatment